68
Management
Table 19. Lipid-Lowering Agents in Childhood and Adolescents
(eg, 10 y for 20 mg dose
Cholesterol absorption inhibitors
Ezetimibe 10 mg PO/d ≥10 y
Bile acid binding
resin
Colesevelam: 3.75 g PO/d as 1
packet or six 625 mg tablets divided
twice daily
≥10 y
PCSK9 monoclonal antibodies
Evolocumab 140 mg SQ every 2 wk or 420 mg
SQ every 2 wk
†
≥10 y
Alirocumab Pediatric dosing by weight in 2- or
4-wk intervals SQ
≥8 y
Other cholesterol-lowering medications
Evinacumab 15 mg/kg IV q 4 wk ≥5 y old HoFH only
Supplements
Psyllium fiber 10 g PO/d
Plant Stanol/Sterol 2 g PO/d (available as capsules or as
food additives)
* e 80 mg dose of simvastatin should not be used due to myopathy risk.
†
e 420 mg dose of evolocumab is no longer manufactured for administration.
